tdp-43-fus-rna-proteinopathy-comparison

TDP-43 and FUS RNA Proteinopathy: Cross-Disease Comparison

Overview

TDP-43 and FUS RNA proteinopathies represent a class of neurodegenerative diseases characterized by the cytoplasmic aggregation of RNA-binding proteins, dysregulated RNA processing, and stress granule dynamics. This comparison examines how these two related protein families manifest across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

TDP-43 (encoded by TARDBP) and FUS (encoded by FUS) are both DNA/RNA-binding proteins with prion-like domains that drive liquid-liquid phase separation (LLPS). Their pathological aggregation defines the majority of ALS cases and a substantial portion of FTD cases. Recent research has revealed that TDP-43 pathology extends beyond ALS-FTD to affect AD, PD, and HD, making cross-disease comparison essential for understanding shared therapeutic targets[@neumann2006][@ling2013].

Cross-Disease Comparison Matrix

TDP-43 Pathology

TDP-43 and FUS RNA Proteinopathy: Cross-Disease Comparison

Overview

TDP-43 and FUS RNA proteinopathies represent a class of neurodegenerative diseases characterized by the cytoplasmic aggregation of RNA-binding proteins, dysregulated RNA processing, and stress granule dynamics. This comparison examines how these two related protein families manifest across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).

TDP-43 (encoded by TARDBP) and FUS (encoded by FUS) are both DNA/RNA-binding proteins with prion-like domains that drive liquid-liquid phase separation (LLPS). Their pathological aggregation defines the majority of ALS cases and a substantial portion of FTD cases. Recent research has revealed that TDP-43 pathology extends beyond ALS-FTD to affect AD, PD, and HD, making cross-disease comparison essential for understanding shared therapeutic targets[@neumann2006][@ling2013].

Cross-Disease Comparison Matrix

TDP-43 Pathology

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---------|-------------------|-------------------|-----|----------------------|-------------------|
| TDP-43 inclusions | Common (50-60% AD) | Moderate (30-40% PD) | >95% ALS cases | ~50% FTD cases | Rare (co-pathology) |
| Inclusion type | Cytoplasmic NFTs | Lewy body co-pathology | NCIs, skein-like | Diverse (Types A-D) | Sparse, cytoplasmic |
| Phospho-TDP-43 (S409/410) | Yes, in limbic regions | Yes, variable | Strong positivity | Strong positivity | Rare |
| C-terminal fragments | 25kDa, 35kDa | Variable | Prominent | Prominent | Not prominent |
| Nuclear loss | Early event | Moderate | Severe | Severe | Mild |
| TARDBP mutations | Not associated | Not associated | ~5% familial ALS | Rare | None reported |
| C9orf72 influence | Not prominent | Not prominent | Primary cause | Primary cause | None |
| Stress granule involvement | Moderate | Variable | Severe | Severe | Moderate |
| Propagation pattern | Braak-like staging | Brainstem to cortex | Multi-focal | Multi-focal | Striatal to cortical |

FUS Pathology

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---------|-------------------|-------------------|-----|----------------------|-------------------|
| FUS inclusions | Rare | Rare | ~5% familial ALS | ~10% FTD (FTLD-FUS) | Rare |
| Inclusion type | Sparse, nuclear | Very rare | Cytoplasmic in motor neurons | FTLD-FUS subtypes | Sparse |
| FUS mutations | Not associated | Not associated | ~5% familial ALS | Rare | None reported |
| Phase separation dysregulation | Not prominent | Not prominent | Severe | Severe | Moderate |
| Cytoplasmic mislocalization | Minimal | Minimal | Marked (NLS mutations) | Moderate | Mild |
| P525L mutation | Not present | Not present | Severe, juvenile | Rare | None |
| R521C mutation | Not present | Not present | Most common adult | Rare | None |
| Stress granule incorporation | Minimal | Minimal | Severe | Severe | Moderate |
| Nucleocytoplasmic transport defect | Mild | Mild | Severe | Severe | Moderate |

RNA Splicing Dysregulation

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---------|-------------------|-------------------|-----|----------------------|-------------------|
| TDP-43 splicing targets | Moderate disruption | Moderate disruption | Severe disruption | Severe disruption | Mild |
| FUS splicing targets | Minimal | Minimal | Severe | Severe | Minimal |
| KCNQ2 mis-splicing | Not reported | Not reported | Documented[@joseph2025] | Documented | Not reported |
| Cryptic polyadenylation | Not reported | Not reported | Documented[@bryce-smith2025] | Documented | Not reported |
| UPF1 dysfunction | Not reported | Not reported | Documented[@alessandrini2026] | Documented | Not reported |
| NMD pathway impairment | Mild | Mild | Severe | Severe | Moderate |
| Alternative splicing changes | 100s of transcripts | 100s of transcripts | 100s of transcripts | 100s of transcripts | 50-100 transcripts |
| Neuronal transcript specificity | High | High | Very high | Very high | Moderate |

Stress Granule Dynamics

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---------|-------------------|-------------------|-----|----------------------|-------------------|
| SG formation | Moderate increase | Variable | Severe increase | Severe increase | Moderate |
| LLPS dysregulation | Aβ-mediated | LRRK2-mediated | TDP-43/FUS-mediated | TDP-43/FUS-mediated | mHTT-mediated |
| G3BP1 sequestration | Mild | Variable | Severe | Severe | Mild |
| TIA-1 alterations | Mild | Moderate | Severe | Severe | Not prominent |
| Persistent stress granules | Rare | Rare | Common | Common | Variable |
| Solidification transition | Occurs | Occurs | Frequent | Frequent | Occurs |
| Clearance via autophagy | Impaired (mTOR) | Impaired (LRRK2) | Impaired | Impaired | Impaired (mHTT) |
| Demixing within SGs | Not well characterized | Not well characterized | Documented[@yan2025] | Documented | Not well characterized |

Nucleocytoplasmic Transport

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---------|-------------------|-------------------|-----|----------------------|-------------------|
| Nuclear import defects | Moderate | Moderate (LRRK2) | Severe | Severe | Moderate |
| Nuclear export enhancement | Mild | Mild | Severe | Severe | Mild |
| Importin-α/β dysfunction | Not prominent | LRRK2-mediated | TDP-43/FUS mutations | TDP-43 mutations | Not prominent |
| NPC integrity | Impaired | Impaired | Severely impaired | Severely impaired | Moderately impaired |
| Ran-GTP gradient disruption | Mild | Mild | Severe | Severe | Moderate |
| NLS mutations | None | None | FUS P525L, R521C | Rare | None |
| Ribosomal protein sequestration | Mild | Mild | Severe | Severe | Moderate |

Molecular Mechanisms

TDP-43 Normal Function and Pathology

TDP-43 is a 414-amino acid RNA-binding protein with distinct structural domains that govern its normal function and pathogenicity[@dormann2011]:

Normal Functions:

• Transcriptional regulation via DNA/RNA binding
• Alternative splicing regulation of neuronal transcripts
• mRNA stability and transport
• Stress granule dynamics
• microRNA biogenesis

FUS Normal Function and Pathology

FUS is a 526-amino acid RNA-binding protein with structural features shared with TDP-43 and the FET protein family[@murakami2015][@kwok2020]:

Normal Functions:

• Transcriptional regulation with RNA Pol II
• Alternative splicing regulation
• RNA transport and local translation in dendrites
• DNA damage response
• Stress granule formation

• P525L: Loss of NLS, severe cytoplasmic mislocalization, juvenile-onset
• R521C: Most common adult-onset FUS-ALS mutation
• R522G, R521H: Additional pathogenic variants

Shared RNA Splicing Dysregulation

Both TDP-43 and FUS regulate overlapping sets of RNA targets, and their dysfunction causes convergent splicing defects[@joseph2025][@bryce-smith2025][@alessandrini2026]:

Key Shared Targets:

• KCNQ2: Potassium channel mis-splicing causes neuronal hyperexcitability
• UNC13A: Synaptic vesicle release machinery
• STAG2: Nuclear architecture
• PGAM1: Energy metabolism

Cross-Disease Manifestations

TDP-43 in Alzheimer's Disease

TDP-43 pathology is highly prevalent in AD, affecting 50-60% of cases[@jeong2023]:

Clinical Significance:

• TDP-43 pathology in AD predicts more rapid cognitive decline
• Limbic predominance (hippocampus, amygdala) with variable cortical spread
• Co-existence with tau pathology (neurofibrillary tangles) and amyloid plaques
• TDP-43 inclusions are pSer409/410-positive, similar to ALS/FTD

• Aβ oligomers promote TDP-43 mislocalization through oxidative stress
• Tau pathology synergizes with TDP-43 to accelerate neurodegeneration
• Age-related decline in nuclear import capacity predisposes to TDP-43 pathology

• Autophagy enhancers (trehalose, rapamycin) may promote TDP-43 clearance
• Phase separation modulators could prevent liquid-to-solid transition

TDP-43 in Parkinson's Disease

TDP-43 co-pathology occurs in 30-40% of PD cases, particularly in advanced disease:

Clinical Significance:

• TDP-43 in PD associated with cognitive impairment and dementia
• Limbic and cortical involvement in PD-dementia spectrum
• Co-localization with alpha-synuclein inclusions in some cases

• Alpha-synuclein may promote TDP-43 aggregation through cross-seeding
• LRRK2 mutations affect stress granule dynamics and nuclear transport
• Common downstream pathways (autophagy dysfunction, mitochondrial stress)

• LRRK2 inhibitors may indirectly reduce TDP-43 pathology
• Dual targeting of alpha-synuclein and TDP-43 aggregates

TDP-43 and FUS in ALS

ALS represents the paradigmatic disease for RNA proteinopathies[@ling2013][@kwok2020]:

TDP-43-ALS (>95% of ALS cases):

• Sporadic and familial forms both show TDP-43 pathology
• TARDBP mutations account for ~5% of familial ALS
• C9orf72 expansion leads to TDP-43 pathology as final common pathway
• Nuclear loss-of-function precedes cytoplasmic aggregation

• Mutations cause direct FUS pathology
• P525L: severe, juvenile-onset, rapid progression
• R521C: most common adult-onset
• FUS inclusions are TDP-43-negative (distinguishing from TDP-43-ALS)

• Rapid motor neuron degeneration (upper and lower)
• Bulbar onset in many cases
• Cognitive/behavioral involvement in ~50% (ALS-FTD spectrum)

TDP-43 and FUS in Frontotemporal Dementia

FTD represents the cognitive counterpart to ALS within the disease spectrum[@dormann2011]:

TDP-43-FTD (FTLD-TDP, ~50% of FTD):

• Four pathological subtypes (Types A-D) with distinct patterns
• Type A: GRN mutations (multiple small inclusions in layer 2)
• Type B: C9orf72 expansion (moderate inclusions throughout cortex)
• Type C: Semantic variant PPA (long dystrophic neurites)
• Type D: VCP mutations (striatal inclusions)

• Includes atypical FTLD with FUS pathology (aFTLD-U)
• Neuronal intermediate filament inclusion disease (NIFID)
• Basophilic inclusion body disease (BIBD)
• FUS-positive, TDP-43-negative, tau-negative

• Behavioral variant FTD: disinhibition, apathy, loss of empathy
• Primary progressive aphasia variants
• Motor features in FTD-ALS overlap

TDP-43 and FUS in Huntington's Disease

RNA proteinopathy is less prominent in HD but shows overlapping mechanisms:

TDP-43 in HD:

• Rare TDP-43 inclusions in HD brain
• mHTT may indirectly promote TDP-43 aggregation
• Co-pathology in HD with AD/PD features

• Minimal FUS pathology
• mHTT does not directly affect FUS localization

Stress Granule Dynamics Across Diseases

Stress granules serve as critical intermediates in RNA proteinopathy pathogenesis[@wolozin2019][@gasset2024]:

Shared Stress Granule Mechanisms

Normal SG Function:

• Temporary storage of translationally arrested mRNAs
• Protection during cellular stress
• Selective autophagy of SG components

• Enhanced recruitment of TDP-43/FUS to SGs
• Prolonged SG persistence due to impaired clearance
• Liquid-to-solid phase transition within SGs
• Demixing of TDP-43 within stress granules creating pathological microdomains[@yan2025]

Disease-Specific SG Modifiers

| Disease | Primary SG Modifier | Mechanism |
|---------|--------------------|-----------|
| AD | Aβ oligomers | eIF2α phosphorylation, oxidative stress |
| PD | LRRK2 mutations | Rab GTPase cycle, trafficking defects |
| ALS | TDP-43/FUS mutations | Prion-like domain alterations, NLS mutations |
| FTD | TDP-43/FUS mutations | Same as ALS, converging pathways |
| HD | mHTT | Interference with SG dynamics, autophagy defects |

Therapeutic Targeting of Stress Granules

Phase Separation Modulators:

• Small molecules targeting LLPS thermodynamics
• Compounds preventing liquid-to-solid transition[@gasset2024]
• HSP104-based disaggregases under development

• mTOR inhibitors (rapamycin, temsirolimus)
• AMPK activators (metformin)
• Trehalose (natural disaccharide, TFEB activator)

Nucleocytoplasmic Transport Defects

Impaired nucleocytoplasmic transport is a shared feature across RNA proteinopathies[@buttner2020][@chen2019]:

Common Mechanisms

Nuclear Import Impairment:

• TDP-43/FUS mutations disrupt NLS function
• Importin-α/β dysfunction
• Ran-GTP gradient disruption

• Hyperphosphorylation exposes nuclear export signals
• CRM1-mediated export enhancement
• Cytoplasmic accumulation

Disease-Specific Transport Defects

| Disease | Primary Defect | Molecular Link |
|---------|---------------|----------------|
| AD | Moderate import impairment | Aging, Aβ toxicity |
| PD | LRRK2-mediated Rab dysfunction | RAB29, RAB10, RAB8A |
| ALS | NLS mutations (FUS), phosphorylation (TDP-43) | Direct protein dysfunction |
| FTD | Same as ALS | Same as ALS |
| HD | NPC integrity impairment | mHTT-mediated |

Therapeutic Targets

• Importin modulators restoring nuclear import
• Nuclear export inhibitors (selective)
• Ran-GTP gradient enhancers
• NPC repair mechanisms

Therapeutic Targets

Preclinical and Clinical Approaches

| Target | Approach | Disease | Development Stage |
|--------|----------|---------|-------------------|
| TDP-43 expression | ASO silencing | ALS, FTD | Phase 1-2 |
| FUS expression | ASO targeting | FUS-ALS | Preclinical |
| C9orf72 repeat | ASO, small molecules | ALS, FTD | Phase 1-2 |
| Aggregation | Small molecule inhibitors | ALS, FTD, AD | Preclinical |
| Phase separation | LLPS modulators | ALS, FTD | Preclinical |
| Stress granules | SG dynamics modulators | ALS, FTD, AD, PD | Preclinical |
| Autophagy | TFEB activators, mTOR inhibitors | ALS, FTD, AD, PD | Preclinical |
| Nuclear import | Importin modulators | ALS, FTD | Research |
| KCNQ2 splicing | ASO correction | ALS, FTD | Preclinical |
| YAP signaling | YAP activators | ALS, FTD | Research[@zhang2025] |
| SUMOylation | SUMO2/3 enhancers | ALS, FTD | Research |
| NMD pathway | UPF1 modulators | ALS, FTD | Research |

Clinical Trials

Active/Recruiting ALS-FTD Trials:

Biomarkers

Fluid Biomarkers

| Biomarker | Source | Disease | Clinical Use |
|-----------|--------|---------|--------------|
| Phospho-TDP-43 (S409/410) | CSF, plasma | ALS, FTD, AD, PD | Disease-specific marker |
| Total TDP-43 | CSF, plasma | ALS, FTD | Disease activity marker |
| Neurofilament light (NfL) | CSF, plasma | ALS, FTD, AD, PD | Progression, prognosis |
| Neurofilament heavy (NfH) | CSF, plasma | ALS | Prognosis |
| CSF TDP-43 | CSF | ALS, FTD | Diagnostic |
| FUS in CSF | CSF | FUS-ALS, FUS-FTD | Diagnostic (emerging) |

Imaging Biomarkers

• MRI: Cortical thinning patterns in motor and frontal regions
• PET: Frontal/temporal hypometabolism in FTD
• DTI: White matter tract involvement (corticospinal tract)

Mermaid Diagram: Cross-Disease RNA Proteinopathy Network

Cross-Links

Related Mechanisms

• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [FUS Proteinopathy](/mechanisms/fus-proteinopathy)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [Stress Granule Dysfunction Cross-Disease Comparison](/mechanisms/stress-granule-disease-comparison)
• [ALS TDP-43 Pathway](/mechanisms/als-tdp43-pathway)
• [FUS ALS-FTD Causal Chain](/mechanisms/fus-als-ftd-causal-chain)
• [Nucleocytoplasmic Transport Defects](/mechanisms/nucleocytoplasmic-transport-defects)
• [RNA Splicing Defects](/mechanisms/rna-splicing-defects)

Related Diseases

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/als)
• [Frontotemporal Dementia (FTD)](/diseases/ftd)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons-disease)

Related Proteins and Genes

• [TDP-43](/proteins/tdp-43)
• [FUS](/proteins/fus-protein)
• [TARDBP](/genes/tardbp)
• [FUS](/genes/fus)
• [C9orf72](/entities/c9orf72)

References

: [Neumann M, et al, Ubiquitinated TDP-43 in FTLD and ALS (2006)](https://doi.org/10.1126/science.1134108)
: [Ling SC, et al, Converging mechanisms in ALS and FTD (2013)](https://doi.org/10.1016/j.neuron.2013.07.033)
: [Dormann D, Haass C, TDP-43 and FUS nuclear protein aggregation (2011)](https://doi.org/10.1038/emboj.2011.134)
: [Murakami T, et al, ALS/FTD mutation-induced phase transition of FUS (2015)](https://doi.org/10.1016/j.neuron.2015.08.020)
: [Kwok CT, et al, FUS-ALS clinical features and genetic heterogeneity (2020)](https://doi.org/10.1136/jnnp-2020-323588)
: [Buttner S, et al, FUS-mediated nuclear transport in ALS (2020)](https://doi.org/10.1038/s41582-020-0356-0)
: [Wolozin B, Ivanov P, Stress granules and neurodegeneration (2019)](https://doi.org/10.1038/s41583-019-0194-5)
: [Yan X, et al, Intra-condensate demixing of TDP-43 (2025)](https://pubmed.ncbi.nlm.nih.gov/40412392/)
: [Scialò C, et al, Seeded aggregation of TDP-43 (2025)](https://pubmed.ncbi.nlm.nih.gov/40157355/)
: [Joseph BJ, et al, TDP-43 mis-splicing of KCNQ2 (2025)](https://pubmed.ncbi.nlm.nih.gov/41174170/)
: [Bryce-Smith S, et al, TDP-43 loss induces cryptic polyadenylation (2025)](https://pubmed.ncbi.nlm.nih.gov/41120751/)
: [Alessandrini F, et al, TDP-43 dysfunction compromises UPF1 (2026)](https://pubmed.ncbi.nlm.nih.gov/41389796/)
: [Zhang J, et al, YAP maintains TDP-43 condensates (2025)](https://pubmed.ncbi.nlm.nih.gov/40542195/)
: [Chen Y, Cohen TJ, Aggregation of RNA-binding proteins in ALS/FTD (2019)](https://doi.org/10.1016/j.tins.2019.01.003)
: [Kim HJ, et al, Mutations in prion-like domains cause multisystem proteinopathy (2013)](https://doi.org/10.1038/nature11922)
: [Gasset-Rosa F, et al, Targeting phase separation in ALS/FTD (2024)](https://doi.org/10.1016/j.tins.2023.11.005)
: [Shenoy J, et al, FUS aggregates from LLPS to amyloid fibrils (2023)](https://doi.org/10.1186/s40478-023-01581-4)
: [Serris A, et al, The many faces of TDP-43 (2022)](https://doi.org/10.1007/s00401-022-02432-7)
: [Gal J, RNA granules in neurodegeneration (2023)](https://doi.org/10.1016/j.nbd.2023.106084)
: [Jeong YH, TDP-43 pathology in AD and LBD (2023)](https://doi.org/10.1093/jnen/nlac132)
: [Urwin H, et al, TDP-43 and FUS in ALS and FTD (2020)](https://doi.org/10.1007/978-981-32-9358-8_4)